Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Biliary tract cancers—rare malignancies arising in the gallbladder, bile ducts and related structures—are associated with poor outcomes.
Three checkpoint inhibitors reduce the risk of death for patients with hard-to-treat liver and biliary tract cancers.
The IDH1 inhibitor is the third medication approved this year for hard-to-treat bile duct cancer.
These are the latest cancer treatments approved by the FDA.
Over a third of bile duct cancer patients treated with the kinase inhibitor experienced complete or partial tumor remission.
New site-agnostic therapies highlight the importance of genetic testing.
IDH1 inhibitor delayed progression of this often aggressive cancer of the bile ducts.
The “LazyTown” actor had bile duct cancer.
Cancer cells can be retrieved during such autopsies and kept alive, allowing researchers to experiment with ways to treat — or kill — them...
Know you are not alone. Many others have had your experience, including me.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.